Baxter caught up in China bribery scandal

"Bribery" is the word on everyone's mind in China as the GlaxoSmithKline ($GSK) bribery probe deepens and expands out toward other drugmakers. Big Pharma companies are fighting to stay out of the spotlight as authorities show up to visit them. But Thursday, Baxter International ($BAX) found itself in the hot seat for expense violations it found last year. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.